Clinical Trial Detail

NCT ID NCT02466568
Title Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung adenocarcinoma

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.